Sona Nanotech Inc C.SONA

Alternate Symbol(s): SNANF

Technology Scientific & Technical Instruments

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.

CSE:SONA - Post by User

Sona Nanotech Inc > email from yesterday

<< Previous

Bullboard Posts

Next >>

Comment by shoosh22on Aug 14, 2020 4:29pm

263 Views

Post# 31410605

RE:email from yesterday

Thanks very much for sharing that newbieontario64. I heard the same from David we are on schedule and results will be released within the 2 week time frame. Next week for sure.. A long wait but what a pay off. Sona will be third approved, but best Antigen Test so far. Nobody has come close.

newbieontario64 wrote: Hi James – we press released that we expect to be able to release evaluation results “within two weeks” and there has been no change to that.
We have an antigen test that works, which is an extraordinary thing. In seven months, amongst all the large, well resourced life sciences companies in the world, only two have gained FDA EUA. Sona intends to be the third. We just need sufficient results from an in-field evaluation study to support our FDA and HC submissions.
Many thanks.

David Regan | CEO

“Transforming Point of care, powering the next generation of lateral flow tests and building pioneering partnerships”
www.sonanano.com
M: +1-902-448-1416 | Skype: dregan07